Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
Authors
Keywords
-
Journal
DIABETOLOGIA
Volume 55, Issue 10, Pages 2593-2603
Publisher
Springer Nature
Online
2012-08-09
DOI
10.1007/s00125-012-2653-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice
- (2016) Vladimir N. Anisimov et al. Aging-US
- Mortality After Incident Cancer in People With and Without Type 2 Diabetes: Impact of metformin on survival
- (2012) C. J. Currie et al. DIABETES CARE
- Metformin Inhibits Growth of Thyroid Carcinoma Cells, Suppresses Self-Renewal of Derived Cancer Stem Cells, and Potentiates the Effect of Chemotherapeutic Agents
- (2012) Guofang Chen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
- (2012) Hiroshi Noto et al. PLoS One
- Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals
- (2011) Meei-Shyuan Lee et al. BMC CANCER
- Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells
- (2011) B. Bao et al. Cancer Prevention Research
- Metformin, diet and breast cancer: An avenue for chemoprevention
- (2011) Paola Muti et al. CELL CYCLE
- Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
- (2011) A. Ferrara et al. DIABETES CARE
- Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives: Results from a large population-based follow-up study
- (2011) R. Ruiter et al. DIABETES CARE
- Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
- (2011) A. Pfützner et al. DIABETES OBESITY & METABOLISM
- Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153
- (2011) N. WU et al. NEOPLASMA
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
- (2010) A. DeCensi et al. Cancer Prevention Research
- Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
- (2010) D. Williams-Herman et al. DIABETES OBESITY & METABOLISM
- Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials
- (2010) J. A. Johnson et al. DIABETOLOGIA
- Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
- (2010) P. D. Home et al. DIABETOLOGIA
- Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure
- (2010) S. L. Bowker et al. DIABETOLOGIA
- New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes
- (2009) G. Libby et al. DIABETES CARE
- Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16
- (2009) G. W.D. Landman et al. DIABETES CARE
- Combined randomised controlled trial experience of malignancies in studies using insulin glargine
- (2009) P. D. Home et al. DIABETOLOGIA
- The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
- (2009) C. J. Currie et al. DIABETOLOGIA
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials
- (2008) M. Monami et al. DIABETES CARE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More